This paper details the establishment and initial findings of the Global Neurodegeneration Proteomics Consortium (GNPC), a public-private partnership aimed at accelerating the discovery of biomarkers and drug targets for common neurodegenerative diseases like Alzheimer’s, Parkinson’s, Frontotemporal Dementia, and ALS. By assembling one of the world's largest harmonized proteomic datasets from over 35,000 biofluid samples, the consortium overcomes previous barriers related to fragmented research and data sharing. Initial analyses demonstrate the utility of the dataset by identifying disease-specific protein changes, establishing a transdiagnostic signature of clinical severity, and revealing distinct patterns of accelerated organ aging across conditions. Furthermore, the research pinpointed a robust, disease-independent proteomic signature linked to the APOE $\varepsilon$4 genetic risk factor. The overall goal is to make this extensive dataset publicly accessible in July 2025 to foster further international collaboration and drive the development of new diagnostics and precision treatments.

References:

• Imam F, Saloner R, Vogel J W, et al. The Global Neurodegeneration Proteomics Consortium: biomarker and drug target discovery for common neurodegenerative diseases and aging[J]. Nature Medicine, 2025: 1-11.